Misraim announces the partnership with the giant Chinese Jiangso Henguri Pharmaceuticals. Misraim according to this partnership will be the Marketing Authorization Holder (MAH) for the novel anti-fungal, Caspofungin Acetate 50mg.  We are continuing our negotiation to involve other critical care and oncology medications to enrich our portfolio in Iraq. We expect that this partnership will strengthen the positions of the two companies in Iraq notably in public tender business.